NPLEx Brings A ‘Quiet’ Year On State PSE Legislation – CHPA
This article was originally published in The Tan Sheet
Executive Summary
CHPA President and CEO Scott Melville says 2015 is the “quietest” in five years for state legislation on the sale of pseudoephedrine, a testament to NPLEx. Bills for Rx-only PSE sales introduced in four states this year failed.
You may also be interested in...
State Lawmakers Likely To Deal Questions About Oral Phenylephrine Into 2024 Legislation Deck
State government authority is limited to make changes concerning OTC sales, including oral products with phenylephrine. “As we've learned in the past, that hasn't stopped them before. We're going to be monitoring this very closely going into next year,” says CHPA state legislature lobby chief Carlos Gutierrez.
Electronic Tracking Success Could End Rx-Only Pseudoephedrine In Mississippi
Former Mississippi Gov. Haley Barbour says industry should ask state legislators to repeal the 2010 law that made all PSE drugs Rx-only. CHPA “might get some listeners” if it highlights how the tracking system places less of a financial burden on consumers and the health care system, he says.
IFF Narrows Focus To Fragrance, Health, Food
International Flavors & Fragrances agrees to sell its Pharma Solutions business to plant-based ingredients company Roquette for an enterprise value of $2.85bn to reduce debt and streamline its business to three segments, including scents.